Lykos, the developer of the MDMA-assisted therapy for PTSD, called the FDA’s request for more phase 3 research “deeply disappointing.”
FDA Holds Back MDMA Psychedelic Therapy Over Safety, Efficacy Concerns
Best place to learn & earn
Best place to learn & earn
Lykos, the developer of the MDMA-assisted therapy for PTSD, called the FDA’s request for more phase 3 research “deeply disappointing.”